CG001 attenuates complement-mediated glomerular lesions in a rat MsPGN model. (A-D) HE, PAS staining, and immunostaining for proliferating cell nuclear antigen (PCNA) and C3d in kidney tissue sections collected from anti-Thy1 nephritic rats on day 7 after treatment with CG001. (A) Representative photomicrographs of glomeruli and (B) quantitative results of total cell counts, (C) PCNA-positive cell counts in the glomeruli and (D) C3d deposition. Arrows indicate the increased mesangial cellularity, and stars indicate the thickened capillary walls and glomerular basement membrane. (E-F) Effect of CG001 treatment on 24-hour urinary protein collected at the indicated time points. Data are presented as (E) individual and (F) combined results (mean ± SEM); n = 4 (negative control, NC), 8 (rabbit anti-Thy1 serum, anti-rat thymocyte serum [ATS] alone treatment), or 6 (additive CG001 treatment). ∗ P < .05, ∗∗∗P < .001, and ∗∗∗∗P < .0001.